Angle Share Discussion Threads

[gspanner] 18/11/2024 09:50

Happy to eat my humble pie…

[sawney] 18/11/2024 09:41

Got your knife and fork...?It'll probably drop back this afternoon but no harm in enjoying the moment....

[mesquida] 18/11/2024 09:33

You are on the wrong thread m_knight10, this is the ANGLE thread .

[m_night10] 18/11/2024 09:25

#POLX next less than half the mcap of #AGL but a stronger cash position and higher revenues and growth.

POLX Polarean Imaging 1.6p I fancy to fill the gap to 3.2p and head to 10p+. Mcap is peanuts and cash position is much longer to Q2 2026 and revenue are higher and growing even more quickly than this.. I see it as a steal for the FDA approved Xenon MRI. No company debt, masssive growth potential in the worlds biggest health market the United States where it's already in 21 clinical settings, best in class next generation MRI. Revenues rising up 3000% to $3mil for 2024 and doubling again next to $6mil in 2025 Cash runway to minimum of Q2 2026, looks set to be extended given revenues ahead of expectations.

Putting this UK recovery play potential on radars as used to trade at 100p and has made significant commercial progress since FDA approval.

Massive takeover target and will be sold for 20p+ share price.

1. September 18th 2024: Interventional radiology vendor Merit Medical to acquire device portfolio for $210M.

APPROX 13P SHARE PRICE EQUIVALENT FOR POLX


2. September 25th 2024: Private equity firm acquiring diagnostic imaging provider for $658M

APPROX 48P SHARE PRICE EQUIVALENT FOR POLX


3. October 14th 2024: Hologic to Acquire Gynesonics The women’s health company will be purchased for approximately $350 million.

APPROX 22P SHARE PRICE EQUIVALENT FOR POLX

4. Bracco current major TR1 Holder of Polarean splashed out $450MILLION for a diagnostic buyout

POLX easy buyout target more massive premiums as per the above imv. DYOR, not advice.

[ericthebrown] 18/11/2024 08:53

Up 8.7% now. On way back to plaing price of 15p a share maybe? Bid 12, ask 13p.

[robizm] 18/11/2024 08:27

With over £100 million invested and waiting years, I want to see results from Angle.

[boris cobaka] 18/11/2024 08:22

hxxps://www.astrazeneca.com/media-centre/press-releases/2024/tagrisso-recommended-for-eu-approval-laura.html

Interesting news. Imagine a companion diagnostic treatment that could quickly and accurately provide important data to assist in the decision making process.

[gspanner] 18/11/2024 08:18

Much as I’d love it Eric I don’t think a small daily mail tip makes much different these days…. I would be delighted to eat my words….

[m_night10] 18/11/2024 07:21

POLX Polarean Imaging 1.6p I fancy to fill the gap to 3.2p and head to 10p+. Mcap is peanuts and cash position is much longer to Q2 2026 and revenue are higher and growing even more quickly than this.. I see it as a steal for the FDA approved Xenon MRI. No company debt, masssive growth potential in the worlds biggest health market the United States where it's already in 21 clinical settings, best in class next generation MRI. Revenues rising up 3000% to $3mil for 2024 and doubling again next to $6mil in 2025 Cash runway to minimum of Q2 2026, looks set to be extended given revenues ahead of expectations.

Putting this UK recovery play potential on radars as used to trade at 100p and has made significant commercial progress since FDA approval.

Massive takeover target and will be sold for 20p+ share price.

1. September 18th 2024: Interventional radiology vendor Merit Medical to acquire device portfolio for $210M.

APPROX 13P SHARE PRICE EQUIVALENT FOR POLX


2. September 25th 2024: Private equity firm acquiring diagnostic imaging provider for $658M

APPROX 48P SHARE PRICE EQUIVALENT FOR POLX


3. October 14th 2024: Hologic to Acquire Gynesonics The women’s health company will be purchased for approximately $350 million.

APPROX 22P SHARE PRICE EQUIVALENT FOR POLX

4. Bracco current major TR1 Holder of Polarean splashed out $450MILLION for a diagnostic buyout

POLX easy buyout target more massive premiums as per the above imv. DYOR, not advice.

[collywobbler] 18/11/2024 07:02

WINK WIIINNNKKK

[collywobbler] 18/11/2024 07:02

HEY TOFEEMAN ……

[waterloo01] 17/11/2024 19:47

I think the point is that once they get beyond research sales and into companion diagnostics the revenues will expand exponentially. Yes it's slower building but it should eventually pay dividends. Too early? That's each investors call.

[divmad] 17/11/2024 19:35

Even with a reduced cost level, Agl is still haemorrhaging cash like crazy. The latest half yearly report showed a £7.7mn loss, albeit reduced from the £9.8mn a year previous. So still running the business at an annualised loss rate of circa £15mn, on current levels of revenue. Until I see a marked step up in those recurring revenues I won't touch Agl, no matter how good the science is supposed to be. Another large placing will happen within the next 6 months, that's for sure, on current business trends.

[purchaseatthetop] 17/11/2024 19:18

Krypton. The issue was always where the bottom was. I bought at 30p and upwards well before FDA approval. I sold a bunch on FDA clearance and then the rest at down to 60p. Thank God. I have bought recently into STX because they are within sight of cash breakeven. Here it remains completely cash burning. Yes there has been a recent rise here. But it will not last without real revenue news. But good luck.

[kryptonsnake] 17/11/2024 15:36

And yet you could have been 50% up if you had purchased at the bottom



sent from my iPhone

[purchaseatthetop] 17/11/2024 13:54

14/7/22 placing at 80. The problem is that zero progress has been made…

Strateg to drive growth over next 12-18 months
ANGLE has continued with its sustained focus on its strategy for achieving widespread adoption of its Parsortix system in the emerging liquid biopsy market. The immediate priorities are to:



· launch the FDA cleared system in the United States, continental Europe and the UK by securing leading clinical laboratories as reference customers

· expand the pharma services business through securing additional customers and repeat business and by establishing molecular capability for high value sample analysis

· establish corporate deals with medtech, pharma and clinical lab companies

[ih_571622] 17/11/2024 10:59

Berenberg 70p price target

ANGLE technology sets the gold standard in cancer diagnostics - investment bank

circulating tumour cell (CTC) technology is the 'gold standard' in cancer diagnostics, according to German investment bank Berenberg in a note in which it reiterated its 'buy' recommendation and 70p price target (the shares are 11.28p)

[thiopia] 16/11/2024 16:52

free stock charts from uk.advfn.com

[thiopia] 16/11/2024 16:48

A good AACR could unlock some Big Pharma contracts or even a strategic investment

[arthur_lame_stocks] 16/11/2024 15:44

PATT

You like a tech punt and will invest in Israeli junk but not something which could revolutionise cancer treatment in as few as 5 years perhaps. It's being tested by the NHS so wait a couple more years and then see where we are. Grail was sold for billions and AIUI Parsortix does more.

[bobbie121] 15/11/2024 20:31

Children behave.

[kryptonsnake] 15/11/2024 17:13

If yas is being positive we must be at a turning point

Did adw die and got reincarnated into PWhite73?



sent from my iPhone